CA2965178C - Thiazolyl-containing compounds for treating proliferative diseases - Google Patents
Thiazolyl-containing compounds for treating proliferative diseases Download PDFInfo
- Publication number
- CA2965178C CA2965178C CA2965178A CA2965178A CA2965178C CA 2965178 C CA2965178 C CA 2965178C CA 2965178 A CA2965178 A CA 2965178A CA 2965178 A CA2965178 A CA 2965178A CA 2965178 C CA2965178 C CA 2965178C
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- certain embodiments
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067178P | 2014-10-22 | 2014-10-22 | |
| US62/067,178 | 2014-10-22 | ||
| PCT/US2015/056899 WO2016065138A1 (en) | 2014-10-22 | 2015-10-22 | Thiazolyl-containing compounds for treating proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2965178A1 CA2965178A1 (en) | 2016-04-28 |
| CA2965178C true CA2965178C (en) | 2023-09-26 |
Family
ID=55761545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2965178A Active CA2965178C (en) | 2014-10-22 | 2015-10-22 | Thiazolyl-containing compounds for treating proliferative diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10112957B2 (enExample) |
| EP (2) | EP3209648B1 (enExample) |
| JP (1) | JP6788583B2 (enExample) |
| AU (1) | AU2015335788B2 (enExample) |
| CA (1) | CA2965178C (enExample) |
| IL (1) | IL251790B (enExample) |
| WO (1) | WO2016065138A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
| EP3484875B1 (en) * | 2016-07-14 | 2021-04-07 | Eli Lilly and Company | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| CN109265455B (zh) * | 2018-11-09 | 2020-08-18 | 新发药业有限公司 | 一种达沙替尼的制备方法 |
| MX2022010391A (es) * | 2020-02-26 | 2022-09-05 | Daewoong Pharmaceutical Co Ltd | Metodo de preparacion de derivados de amina heterociclica. |
| WO2021178485A1 (en) * | 2020-03-06 | 2021-09-10 | National Health Research Institutes | Pyrimidine compounds and their pharmaceutical uses |
| WO2024111626A1 (ja) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | 新規チアゾール誘導体 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| CA2328962A1 (en) | 1998-04-17 | 1999-10-28 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| ID27652A (id) | 1998-08-04 | 2001-04-19 | Astrazeneca Ab | Turunan amida yang digunakan sebagai inhibitor produksi sitokina |
| EP1115707B1 (en) | 1998-09-25 | 2003-11-12 | AstraZeneca AB | Benzamide derivatives and ther use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| EP1546117A2 (en) | 2002-08-14 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ES2571779T3 (es) | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| CA2589773A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| CN101106990B (zh) * | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| US7375951B2 (en) * | 2006-07-07 | 2008-05-20 | Lutron Electronics Co., Inc. | Load control device having a split enclosure |
| EP1912639A4 (en) * | 2005-08-08 | 2011-10-12 | Janssen Pharmaceutica Nv | Thiazolopyrimidine KINASE INHIBITORS |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| DK1957461T3 (en) | 2005-11-14 | 2016-12-19 | Genentech Inc | Bisamidhæmmere the hedgehog-signalling |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| US8067423B2 (en) | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| ES2396366T3 (es) * | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| MX2012002591A (es) | 2009-09-03 | 2012-04-02 | Allergan Inc | Compuestos como moduladores de tirosina cinasas. |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| KR101995013B1 (ko) | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| CN103298794A (zh) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
| US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| BR112013029640A2 (pt) | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
| LT2718270T (lt) * | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| WO2013050261A1 (en) | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| CN104024257A (zh) | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Pi3k的新的喹喔啉抑制剂 |
| BR112014010439A2 (pt) | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
-
2015
- 2015-10-22 JP JP2017522375A patent/JP6788583B2/ja active Active
- 2015-10-22 EP EP15852450.4A patent/EP3209648B1/en active Active
- 2015-10-22 EP EP20161511.9A patent/EP3715346B1/en active Active
- 2015-10-22 AU AU2015335788A patent/AU2015335788B2/en active Active
- 2015-10-22 WO PCT/US2015/056899 patent/WO2016065138A1/en not_active Ceased
- 2015-10-22 CA CA2965178A patent/CA2965178C/en active Active
- 2015-10-22 US US15/518,541 patent/US10112957B2/en active Active
-
2017
- 2017-04-19 IL IL251790A patent/IL251790B/en active IP Right Grant
-
2018
- 2018-10-24 US US16/169,972 patent/US10464949B2/en not_active Expired - Fee Related
-
2019
- 2019-11-01 US US16/672,198 patent/US10844077B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016065138A1 (en) | 2016-04-28 |
| US20200165267A1 (en) | 2020-05-28 |
| US20170233411A1 (en) | 2017-08-17 |
| IL251790B (en) | 2019-08-29 |
| US10844077B2 (en) | 2020-11-24 |
| US10112957B2 (en) | 2018-10-30 |
| AU2015335788A1 (en) | 2017-05-04 |
| US20190119301A1 (en) | 2019-04-25 |
| US10464949B2 (en) | 2019-11-05 |
| AU2015335788B2 (en) | 2020-07-30 |
| JP6788583B2 (ja) | 2020-11-25 |
| EP3715346A1 (en) | 2020-09-30 |
| CA2965178A1 (en) | 2016-04-28 |
| EP3715346B1 (en) | 2024-01-03 |
| IL251790A0 (en) | 2017-06-29 |
| EP3209648B1 (en) | 2020-03-11 |
| EP3209648A1 (en) | 2017-08-30 |
| JP2017537886A (ja) | 2017-12-21 |
| EP3209648A4 (en) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7200282B2 (ja) | サイクリン依存性キナーゼの阻害剤 | |
| CA2965178C (en) | Thiazolyl-containing compounds for treating proliferative diseases | |
| AU2016283105B2 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| AU2015371251B2 (en) | Inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| US10342798B2 (en) | Fused bicyclic pyrimidine derivatives and uses thereof | |
| AU2019413694B2 (en) | Inhibitors of cyclin-dependent kinase 7 and uses thereof | |
| AU2020357983B2 (en) | Tricyclic kinase inhibitors and uses thereof | |
| CA2996978A1 (en) | Inhibitors of cyclin-dependent kinases | |
| CA2936256A1 (en) | Diazepane derivatives and uses thereof | |
| CA2936871A1 (en) | Dihydropteridinone derivatives and uses thereof | |
| CA2988330C (en) | 4,6-pyrimidinylene derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| EEER | Examination request |
Effective date: 20200917 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 |